Abstract
We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. Automated auditory brainstem evoked response performed at 5 days of age revealed severe hearing impairment. Cranial magnetic resonance (MR) imaging at 11 days of age showed abnormal findings. At 5 weeks of age, VGCV was started. The viral load in blood cells, plasma, and urine decreased during the 6-week treatment. Because of improvement of hearing level and no adverse effects, VGCV was restarted for an additional 6 weeks. Neither the patient’s hearing impairment nor results of cranial MR imaging have become worse in 6 months. It is crucial to gather information from as many cases as possible treated with VGCV to establish a standard protocol for VGCV treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kimberlin DW, Lin CY, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Kiell JM, Soong SJ, Whitley RJ, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003;143:16–25.
Oliver SE, Cloud GA, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Soong SJ, Whitley RJ, Kimberlin DW, National Institute of Allergy, Infectious Diseases Collaborative Antiviral Study Group. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009;46:22–6.
Ogawa H, Suzutani T, Baba Y, Koyano S, Nozawa N, Ishibashi K, Fujieda K, Inoue N, Omori K. Etiology of severe sensorineural hearing loss in children: independent impact of congenital cytomegalovirus infection and GJB2 mutations. J Infect Dis. 2007;195:782–8.
Inoue N. Chapter 84 Human herpesvirus 5 (cytomegalovirus). In: Liu D, editor. Molecular detection of human viral pathogens. Boca Raton: Taylor & Francis/CRC Press; 2010. p 952.
Galli L, Novelli A, Chiappini E, Gervaso P, Cassetta MI, Fallani S, de Martino M. Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. Pediatr Infect Dis J. 2007;26:451–3.
Enjoji M, Goya N, Kurokawa T. Enjoji-shiki Nyuyouji Bunsekiteki Kensahyou. Tokyo: Keioutusin; 1992.
Lombardi G, Garofoli F, Villani P, Tizzoni M, Angelini M, Cusato M, Bollani L, De Silvestri A, Regazzi M, Stronati M. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis. 2009;28:1465–70.
Tanaka-Kitajima N, Sugaya N, Futatani T, Kanegane H, Suzuki C, Oshiro M, Hayakawa M, Futamura M, Morishima T, Kimura H. Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatr Infect Dis J. 2005;24:782–5.
Van der Knaap MS, Vermeulen G, Barkhof F, Hart AA, Loeber JG, Weel JF. Pattern of white matter abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link pattern with congenital cytomegalovirus infection. Radiology. 2004;230:529–36.
Shoji K, Ito N, Ito Y, Inoue N, Adachi S, Fujimaru T, Nakamura T, Nishina S, Azuma N, Saitoh A. Is a 6-week course of ganciclovir therapy effective for chorioretinitis in infants with congenital cytomegalovirus infection? J Pediatr. 2010;157:331–3.
Collaborative Antiviral Study Group Web page. http://www.casg.uab.edu/. Accessed 5 March 2010.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kashiwagi, Y., Kawashima, H., Nakajima, J. et al. Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection. J Infect Chemother 17, 538–540 (2011). https://doi.org/10.1007/s10156-010-0204-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10156-010-0204-z